Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned an average recommendation of "Buy" from the ten analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $23.00.

Several research firms recently issued reports on STOK. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 over the last ninety days. 11.30% of the stock is currently owned by company insiders.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC grew its holdings in Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company's stock valued at $980,000 after buying an additional 47,239 shares in the last quarter. Geode Capital Management LLC lifted its position in Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company's stock valued at $10,705,000 after purchasing an additional 76,661 shares during the last quarter. State Street Corp grew its stake in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after buying an additional 137,145 shares in the last quarter. RTW Investments LP increased its holdings in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after buying an additional 427,447 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock valued at $936,000 after buying an additional 71,647 shares in the last quarter.

Stoke Therapeutics Stock Down 6.6 %

Shares of NASDAQ STOK traded down $0.55 on Friday, reaching $7.74. 1,073,561 shares of the company's stock traded hands, compared to its average volume of 839,762. The business's 50 day simple moving average is $9.46 and its two-hundred day simple moving average is $11.35. Stoke Therapeutics has a 12 month low of $6.29 and a 12 month high of $17.58. The company has a market cap of $418.56 million, a price-to-earnings ratio of -3.69 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.